首页
400-620-6333
切换导航
搜索
基本描述
| 英文名称 | ivabradine |
|---|---|
| 别名 | Corlanor,Corlentor,Procoralan,S-16257 |
| 英文别名 | Corlanor,Corlentor,Procoralan,S-16257 |
名称和标识符
| IUPAC Name | 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one |
|---|---|
| INCHI | InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1 |
| InChi Key | ACRHBAYQBXXRTO-OAQYLSRUSA-N |
| Canonical SMILES | CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC |
| 关联CAS | 155974-00-8 |
| PubChem CID | 132999 |
| MeSH Entry Terms | 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one;Corlanor;ivabradine;S 16257;S 16257 2;S 16257-2;S 162572;S 16260 2;S 16260-2;S 162602;S-16257;S-16257-2;S-16260-2;S16257;S162572;S162 |
数据库链接
| PubChem CID | 132999 |
|---|---|
| Wikipedia | Ivabradine |
| ChEMBL Ligand | CHEMBL471737 |
| BindingDB Ligand | 50326992 |
| CAS Registry No. | 155974-00-8 |
| PEP | ivabradine |
| DrugCentral Ligand | 3312 |
关联配体
| Ligand ID | 2357 |
|---|---|
| 名称 | ivabradine |
| 别名 | Procoralan® |
| 类别 | Synthetic organic |
| 学名 | 3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one |
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
| 评价 | Marketed drugs contain ivabradine hydrochloride (PubChem CID 3045381). |
| 临床描述 |
Postural orthostatic tachycardia syndrome (POTS) occurs in approximately 500,000 Americans,
but predominates in women with a 5:1 ratio. Patients with POTS experience debilitating
tachycardia upon postural changes such as standing that impairs their quality of life.
Tachycardia is clinically defined as a heart rate greater than 100 beats/min; and in POTS
patients, the prolonged heart rate increase is greater than 30 beats/min or increases to 120
beats/min within the first ten minutes of a diagnostic tilt table test without postural
hypotension. There are currently no effective treatment methods for POTS. However, several
studies suggest Ivabradine could be a main treatment option for POTS because Ivabradine
specifically inhibits the f-channels (If) within the sinoatrial (SA) node, which slows the
heart rate. Currently in the US, Ivabradine is mainly prescribed to treat chronic heart
failure. It is well tolerated in patients, but it is not commonly prescribed for POTS. It has
been also used for treatment of inappropriate sinus tachycardia with good benefit. The
hypothesis for this experiment is that Ivabradine will reduce tachycardia and improve
functional status in patients with POTS.
|
| 来源公司 |
University of California, San Diego |
产品问答
产品问答
参考文献
| 1. DiFrancesco D, Camm JA. (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.. Drugs, 64 (16): (1757-65). [PMID:15301560] |
| 2. Mar PL, Raj SR. (2020) Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies.. Annu Rev Med, 71 (13): (235-248). [PMID:31412221] |
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）